Investments, Funding & Disinvestment

Established in 2022, the collaboration combines CytomX’s Probody masking technology with Regeneron’s Veloci-Bi bispecific antibody platform.

The plan follows Arada’s acquisition of a controlling stake in Reem Hospital, marking the company’s entry into the healthcare sector as it expands its presence across non-residential industries.

The initiative will also involve coordination with World Health Organization, Africa Centres for Disease Control and Prevention, and UNICEF to ensure alignment with national outbreak response plans and immunization priorities.

The equipment was officially received by Ministry of Health Permanent Secretary for Donor Coordination, Dr. George Sinyangwe, during a handover ceremony attended by senior government officials and public health leaders.

This new allocation builds on earlier support, which includes US$350 million in Ebola response and broader humanitarian assistance across the DRC, South Sudan, and Uganda.

The funding will support three promising vaccine candidates being developed by Moderna, the University of Oxford in partnership with the Serum Institute of India, and the International AIDS Vaccine Initiative (IAVI).

The company officially listed on the Hong Kong Stock Exchange on June 5, achieving a market valuation of approximately HK$10.7 billion (US$1.37 billion) following its debut.

Ascidian will lead target discovery and selected preclinical activities, while Lilly will oversee additional preclinical development, clinical research, manufacturing, regulatory activities, and global commercialization.

The agreement brings together Pfizer’s global expertise in clinical development, regulatory affairs, and commercialization with Innovent’s strengths in scientific discovery and early-stage oncology research.

The decision expands Imfinzi’s bladder cancer footprint beyond its earlier approval in muscle-invasive bladder cancer (MIBC), where it is used with chemotherapy agents’ gemcitabine and cisplatin before surgery and as a monotherapy afterward.